Keros CSO Lachey transitions to SVP Discovery at 75% time and reduced compensation

Keros Therapeutics, Inc.

Jennifer Lachey's role changes from Chief Scientific Officer to Senior Vice President of Discovery, effective September 1, 2022.
Base salary and unvested option shares reduced to 75% of prior levels; no longer eligible for severance.
Change was at Dr. Lachey's request; she remains employed by the Company.
No longer deemed an 'officer' or 'executive officer' under SEC rules.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jennifer Lachey

Senior Vice President of Discovery

KROS · Keros Therapeutics, Inc.

Effective: 2022-09-01
Filed: August 4, 2022, 7:59 PM ET

She remains employed by the Company and her title has been changed from Chief Scientific Officer to Senior Vice President of Discovery.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Lachey changed role as Senior Vice President of Discovery at Keros Therapeutics, Inc..

Action: changed
Role: Senior Vice President of Discovery

Exact text from the filing

She remains employed by the Company and her title has been changed from Chief Scientific Officer to Senior Vice President of Discovery.

View on SEC.gov

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-22-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.